Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial | Synapse
Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
High immune expression correlates with improved progression-free survival in metastatic CRC patients receiving maintenance therapy.
Mean values of epithelial tumor and stromal cells were analyzed to assess their impact on treatment outcomes in the trial.
Analysis covered various treatment arms, underscoring the significance of the tumor immune microenvironment as a predictive factor.
The findings imply biomarkers may enhance personalized treatment strategies for patients with RAS wt metastatic CRC.
Abstract
Analysis of progression-free survival within the maintenance therapy set by high/low immune expression and treatment arm. Mean Values of Epithelial Tumor and Stromal Cells.